MultNAT® MTC/ RIF Assay
Ongoing Challanges
- According to the World Health Organization (WHO), in 2022, an estimated 10.6 million people worldwide developed tuberculosis, with an incidence rate of 133 per 100,000 population [1] Globally, the prevalence of rifampincin-resistant TB (RR-TB) is approximately 3.3% among new TB cases and about 20% among previously treated cases according to the World Health Organization (WHO) [2] .
REFERENCES:
[1] Global Tuberculosis Report 2023. [2] Global strategy and targets for tuberculosis prevention, care and control after 2015 (Resolution WHA67.1, Agenda item 12.1). da item 12.1). Geneva: World Health Assembly; 2014 (http://apps.who.int/gb/ebwha/pdf_files
Product Overview
The MultNAT® MTC/RIF Assay is designed for the detection of Mycobacterium Tuberculosis Complex (MTC) and Rifampicin (RIF) resistance mutations, utilizing the MultNAT® system.
It features a simple process and integrated system, delivering results in 109 minutes.
- The detected target: TB：IS6110、IS1081、RIF：rpoB
- LOD: TB: 30 CFU/ml、RIF: 800 CFU/ml
This Point-of-Care (POC) Nucleic Acid Test Methodology can be applied in various medical scenarios.
The assay enables accurate detection of MTC and Rifampicin resistance through Nucleic Acid Amplification Test (NAAT) technology.
Clinical Value
- Provides faster detection of TB and Rifampicin resistance, enabling timely treatment initiation.
- Early identification of Rif-resistant TB allows for timely isolation and treatment, preventing the spread of drug-resistant strains.
- POC tests contribute real-time data for monitoring TB and resistance patterns, aiding public health strategie.
